

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address of Company

Izotropic Corporation (the “**Company**”)
15718 39A Avenue
Surrey, BC V3Z 0L1

Item 2. Date of Material Change

October 1, 2018 and October 10, 2018

Item 3. News Release

The News Release dated October 10, 2018 was disseminated by Stockwatch and Market News on October 10, 2018.

Item 4. Summary of Material Change

The Company announced that it has entered into an investor relations consulting agreement (the “**IR Agreement**”) with Robert Lunde (the “**Consultant**”). The term of the IR Agreement commenced on October 1, 2018 and ends on April 1, 2019, unless otherwise terminated as set forth in the IR Agreement. Pursuant to the IR Agreement, the Consultant will provide various investor relations services to the Company in exchange for aggregate consulting fees of \$36,000 and stock options to acquire 100,000 common shares of the Company. In connection with the IR Agreement, on October 10, 2018, the Company granted stock options to the Consultant to acquire 100,000 common shares of the Company at an exercise price of \$0.40 per share for a period of one year from the date of grant. All of the stock options vest immediately as of the date of grant.

Item 5. Full Description of Material Change

5.1 Full Description of Material Change

See attached October 10, 2018 News Release.

5.2 Disclosure for Restructuring Transactions

Not Applicable.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Please contact Robert Thast, Chief Executive Officer of the Company, at 604-542-9458.

Item 9. Date of Report

October 10, 2018

IZOTROPIC CORPORATION

IZOTROPIC CORPORATION ANNOUNCES ENTRY INTO INVESTOR RELATIONS CONSULTING AGREEMENT AND STOCK OPTION GRANT

VANCOUVER, BC – October 10, 2018 – **Izotropic Corporation** (“**Izotropic**” or the “**Company**”) (CSE: IZO) is pleased to announce, that it has entered into an investor relations consulting agreement (the “**IR Agreement**”) with Robert Lunde (the “**Consultant**”). The term of the IR Agreement commenced on October 1, 2018 and ends on April 1, 2019, unless otherwise terminated as set forth in the IR Agreement. Pursuant to the IR Agreement, the Consultant will provide various investor relations services to the Company in exchange for aggregate consulting fees of \$36,000 and stock options to acquire 100,000 common shares of the Company. In connection with the IR Agreement, on October 10, 2018, the Company granted stock options to the Consultant to acquire 100,000 common shares of the Company at an exercise price of \$0.40 per share for a period of one year from the date of grant. All of the stock options vest immediately as of the date of grant.

Robert (Bob) Lunde has over 30 years of public market experience, beginning his career as a floor trader on the Vancouver Stock Exchange in 1982. Bob has since provided fundraising and management services to numerous public companies and was also a founder and director of several public companies in industries ranging from software development to mining enterprises.

About Izotropic

The Company is engaged in the development and commercialization of next generation 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree view acquisition and delivers high diagnostic accuracy.

ON BEHALF OF THE BOARD

“Robert Thast”

Robert Thast

Chief Executive Officer, Director
and Promoter

For further information, please contact:

Robert Thast
Telephone: 604.542.9458

Email: bthast@izocorp.com